Pay in 4 interest-free payments of $6.27 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
This helps the UAE to become a global and regional hub in the pharmaceutical sector
Potential Benefits & Side Effects What the preclinical literature describes
Month 2: momentum builds Average cumulative loss: 4 to 6 percent
Assuming just 10% of eligible beneficiaries use Wegovy in a given year, and assuming a 50% rebate on the list price, Medicare would incur nearly $3 billion in additional net Part D spending for one year for this one drug alone.KFF also finds that beneficiaries who take Wegovy could face monthly out-of-pocket costs of $325 to $430 if they have to pay a percentage of the drugs $1,300 list price for a months supply
US$ 20.38
US$ 22.34
US$ 25.53
US$ 28.48
US$ 21.60
